Clinical Trial Update: Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating re-treatment with ALXN2220 in patients with amyloid transthyretin cardiomyopathy. The trial is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Transthyretin Cardiomyopathy

Drugs mentioned

• ALXN2220

Snippet

Sponsor: Neurimmune AG | Conditions: Amyloid Transthyretin Cardiomyopathy | Phase 2 | Status: ACTIVE_NOT_RECRUITING